Adenovirus-transfected primary cells and methods of pathway mapping

Details for Australian Patent Application No. 2004295706 (hide)

Owner Aventis Pharmaceuticals Inc

Inventors Hahn, Chang S.; Li, Li

Agent Watermark

Pub. Number AU-B-2004295706

PCT Pub. Number WO2005/054485

Priority 60/526,009 01.12.03 US

Filing date 1 December 2004

Wipo publication date 16 June 2005

Acceptance publication date 10 December 2009

International Classifications

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

C07K 14/47 (2006.01) Peptides having more than 20 amino acids

C12N 15/861 (2006.01) Mutation or genetic engineering - Adenoviral vectors

Event Publications

22 June 2006 PCT application entered the National Phase

  PCT publication WO2005/054485 Priority application(s): WO2005/054485

10 December 2009 Application Accepted

  Published as AU-B-2004295706

8 April 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004295711-Deinking system for carbonate pulping

2004295705-A biomimetic composition reinforced by a polyelectrolytic complex of hyaluronic acid and chitosan